Pathogenetic Aspects of Metronomic Administration of Compounds with an Alleged Antitumour Effect (Review)
DOI:
https://doi.org/10.37482/2687-1491-Z151Keywords:
metronomic regimen, anticancer chemotherapy, anticancer drugs, preclinical studies, mechanism of actionAbstract
Chemotherapy is the main treatment method for malignant neoplasms. Classical administration regimens for chemotherapeutic agents are accompanied by strong side effects. Thus, there is a need for a rational mode of administration that can increase the effectiveness of chemotherapy and reduce its side effects. Development of new antitumour drugs must involve testing their pharmacological activity at various administration regimens. At the stage of preclinical studies of new compounds with an alleged antitumour effect, determining an optimal dosage regimen is an urgent task for interdisciplinary research. This article analyses literature on the possible use and effectiveness of metronomic administration of antitumour drugs in clinical practice and in preclinical studies depending on the pathogenetic mechanism of their action. According to recent research, metronomic administration of antitumour and antimetastatic drugs is, undoubtedly, a rational way to solve the problem of severe side effects and poor drug tolerability in cancer patients. The greatest antitumour effectiveness in the metronomic regimen is achieved at combined administration of compounds with different mechanisms of action. In preclinical studies of new antitumour agents, it is important to adhere to the basic principles of developing a metronomic administration regimen: 1) at the testing stage, it is advisable to perform screening administration of low doses of new compounds along with a therapy with a known antitumour drug; 2) the minimum dose of the new compound can be calculated using its maximum tolerated dose (initial approximate series of administration in the amount of 1/10 of the maximum tolerated dose).
Downloads
References
Состояние онкологической помощи населению России в 2021 году / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – фил. ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.
Чубенко В.А., Загорская Л.А., Чубенко В.С., Моисеенко Ф.В., Абдулоева Н.Х., Жабина А.С., Крамчанинов М.М., Шелехова К.В., Мелдо А.А., Зыков Е.М., Кудрявцев А.А., Напольская Е.В., Моисеенко В.М. Метрономная терапия: место в лечении злокачественных опухолей // Практ. онкология. 2019. Т. 20, № 4. С. 289–298. DOI: 10.31917/2004289
Федянин М.Ю., Покатаев И.А., Тюляндин С.А. Метрономные режимы химиотерапии в онкологии // Онкол. колопроктология. 2016. Т. 6, № 1. С. 27–35. DOI: 10.17650/2220-3478-2016-6-1-27-35
Додохова М.А., Алхусейн-Кулягинова М.С., Сафроненко А.В., Котиева И.М., Шпаковский Д.Б., Милаева Е.Р. Влияние цисплатина и гибридного оловоорганического соединения в малых дозах на рост и метастазирование эпидермоидной карциномы Lewis в эксперименте // Эксперим. и клин. фармакология. 2021. Т. 84, № 8. С. 32–35. DOI: 10.30906/0869-2092-2021-84-8-32-35
Wysocki P.J., Lubas M.T., Wysocka M.L. Metronomic Chemotherapy in Prostate Cancer // J. Clin. Med. 2022. Vol. 11, № 10. Art. № 2853. DOI: 10.3390/jcm11102853
Maiti R. Metronomic Chemotherapy // J. Pharmacol. Pharmacother. 2014. Vol. 5, № 3. P. 186–192. DOI: 10.4103/0976-500X.136098
Kerbel R.S. Inhibition of Tumor Angiogenesis as a Strategy to Circumvent Acquired Resistance to Anti-Cancer Therapeutic Agents // Bioessays. 1991. Vol. 13, № 1. P. 31–36. DOI: 10.1002/bies.950130106
Hanahan D., Bergers G., Bergsland E. Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice // J. Clin. Invest. 2000. Vol. 105, № 8. P. 1045–1047. DOI: 10.1172/JCI9872
Qiu H., Wang G.-M. A New Treatment Protocol Targeting Tumor Vasculature – Metronomic Chemotherapy Combined Radiotherapy // Ai Zheng. 2007. Vol. 26, № 12. P. 1392–1396.
Хачатрян Л.А., Щербаков А.П., Чиквина И.И., Николаева Д.М. Новые подходы к решению старой проблемы // Вопр. гематологии/онкологии и иммунопатологии в педиатрии. 2022. Т. 21, № 1. C. 122–135. DOI: 10.24287/1726-1708-2022-21-1-122-135
Norrby K. Metronomic Chemotherapy and Anti-Angiogenesis: Can Upgraded Pre-Clinical Assays Improve Clinical Trials Aimed at Controlling Tumor Growth? // APMIS. 2014. Vol. 122, № 7. P. 565–579. DOI: 10.1111/apm.12201
Kim J.Y., Kim Y.-M. Tumor Endothelial Cells as a Potential Target of Metronomic Chemotherapy // Arch. Pharmacal Res. 2019. Vol. 42, № 1. P. 1–13. DOI: 10.1007/s12272-018-01102-z
Allegrini G., Falcone A., Fioravanti A., Barletta M.T., Orlandi P., Loupakis F., Cerri E., Masi G., Di Paolo A., Kerbel R.S., Danesi R., Del Tacca M., Bocci G. A Pharmacokinetic and Pharmacodynamic Study on Metronomic Irinotecan in Metastatic Colorectal Cancer Patients // Br. J. Cancer. 2008. Vol. 98, № 8. P. 1312–1319. DOI: 10.1038/sаj.bjc.6604311
Cazzaniga M.E., Cordani N., Capici S., Cogliati V., Riva F., Cerrito M.G. Metronomic Chemotherapy // Cancers (Basel). 2021. Vol. 13, № 9. Art. № 2236. DOI: 10.3390/cancers13092236
Krajnak S., Battista M.J., Hasenburg A., Schmidt M. Metronomic Chemotherapy for Metastatic Breast Cancer // Oncol. Res. Treat. 2022. Vol. 45, № 1-2. P. 12–17. DOI: 10.1159/000520236
Chen Y.-P., Liu X., Zhou Q., Yang K.-Y., Jin F., Zhu X.-D., Shi M., Hu G.-Q., Hu W.-H., Sun Y., et al. Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Multicentre, OpenLabel, Parallel-Group, Randomised, Controlled, Phase 3 Trial // Lancet. 2021. Vol. 398, № 10297. P. 303–313. DOI: 10.1016/S0140-6736(21)01123-5
Cazzaniga M.E., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., et al. Metronomic Chemotherapy (mCHT) in Metastatic Triple-Negative Breast Cancer (TNBC) Patients: Results of the VICTOR-6 Study // Breast Cancer Res. Treat. 2021. Vol. 190, № 3. P. 415–424. DOI: 10.1007/s10549-021-06375-5
Banys-Paluchowski M., Ruckhäberle E., Schütz F., Krawczyk N., Fehm T. Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer – a Systematic Review of the Literature // Geburtshilfe Frauenheilkd. 2017. Vol. 77, № 2. P. 142–148. DOI: 10.1055/s-0043-100388
Orlandi P., Di Desidero T., Salvia G., Muscatello B., Francia G., Bocci G. Metronomic Vinorelbine Is Directly Active on Non Small Cell Lung Cancer Cells and Sensitizes the EGFRL858R/T790M Cells to Reversible EGFR Tyrosine Kinase Inhibitors // Biochem. Pharmacol. 2018. Vol. 152. P. 327–337. DOI: 10.1016/j.bcp.2018.04.011
El Darsa H., El Sayed R., Abdel-Rahman O. What Is the Real Value of Metronomic Chemotherapy in the Treatment of Gastrointestinal Cancer? // Expert Opin. Pharmacother. 2021. Vol. 22, № 17. P. 2297–2302. DOI: 10.1080/14656566.2021.1940953
Zsiros E., Lynam S., Attwood K.M., Wang C., Chilakapati S., Gomez E.C., Liu S., Akers S., Lele S., Frederick P.J., Odunsi K. Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial // JAMA Oncol. 2021. Vol. 7, № 1. P. 78–85. DOI: 10.1001/jamaoncol.2020.5945
Bondarenko M., Le Grand M., Shaked Y., Raviv Z., Chapuisat G., Carrère C., Montero M.-P., Rossi M., Pasquier E., Carré M., André N. Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer // Cancers (Basel). 2021. Vol. 13, № 9. Art. № 2239. DOI: 10.3390/cancers13092239
Peristeri D.V., Tepelenis K., Karampa A., Kapodistrias N., Goussia A.C., Pappas-Gogos G., Glantzounis G.K. Metronomic Chemotherapy with Cyclophosphamide for the Treatment of Advanced Hepatocellular Cancer: A Case Report // Ann. Med. Surg. (Lond.). 2021. Vol. 72. Art. № 103043. DOI: 10.1016/j.amsu.2021.103043
Su N.-W., Chen Y.-J. Metronomic Therapy in Oral Squamous Cell Carcinoma // J. Clin. Med. 2021. Vol. 10, № 13. Art. № 2818. DOI: 10.3390/jcm10132818
Isono-Taniguchi R., Goto M., Takimoto Y., Ueda T., Wakimoto Y., Inoue K., Hori K., Ito K., Tsubamoto H. Metronomic Chemotherapy Using Oral Cyclophosphamide and Bevacizumab for Recurrent Cervical Cancer: A MultiInstitutional Retrospective Study // Gynecol. Oncol. Rep. 2022. Vol. 42. Art. № 101013. DOI: 10.1016/j.gore.2022.101013
Sharma A., Kataria B., Biswas B., Bakhshi S., Pushpam D. Oral Metronomic Chemotherapy Is a Cost Effective Alternative to Pazopanib in Advanced Soft Tissue Sarcoma // J. Oncol. Pharm. Pract. 2022. Vol. 28, № 3. P. 560–568. DOI: 10.1177/10781552211000113
Noronha V., Patil V.M., Menon N.S., Joshi A., Goud S., More S., Kannan S., Pawar A., Nakti D., Yadav A., Shah S., Mahajan A., Janu A., Kumar R., Tibdewal A., Mummudi N., Agarwal J.P., Banavali S.D., Prabhash K. Oral Metronomic Chemotherapy After Definitive Chemoradiation in Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial // Esophagus. 2022. Vol. 19, № 4. P. 670–682. DOI: 10.1007/s10388-022-00923-8
Arrivi G., Spada F., Frassoni S., Bagnardi V., Laffi A., Rubino M., Gervaso L., Fazio N. Metronomic Chemotherapy in Patients with Advanced Neuroendocrine Tumors: A Single-Center Retrospective Analysis // J. Neuroendocrinol. 2022. Vol. 34, № 10. Art. № е13189. DOI: 10.1111/jne.13189
Isacoff W.H., Cooper B., Bartlett A., McCarthy B., Yu K.H. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer // Cancers (Basel). 2022. Vol. 14. Art. № 2906. DOI: 10.3390/cancers14122906
Patil V., Noronha V., Dhumal S.B., Joshi A., Menon N., Bhattacharjee A., Kulkarni S., Ankathi S.K., Mahajan A., Sable N., Nawale K., Bhelekar A., Mukadam S., Chandrasekharan A., Das S., Vallathol D., D’Souza H., Kumar A., Agrawal A., Khaddar S., Rathnasamy N., Shenoy R., Kashyap L., Rai R.K., Abraham G., Saha S., Majumdar S., Karuvandan N., Simha V., Babu V., Elamarthi P., Rajpurohit A., Kumar K.A.P., Srikanth A., Ravind R., Banavali S., Prabhash K. Low-Cost Oral Metronomic Chemotherapy versus Intravenous Cisplatin in Patients with Recurrent, Metastatic, Inoperable Head and Neck Carcinoma: An Open-Label, Parallel-Group, Non-Inferiority, Randomised, Phase 3 Trial // Lancet Glob. Health. 2020. Vol. 8, № 9. P. е1213–е1222. DOI: 10.1016/S2214109X(20)30275-8
Simsek C., Esin E., Yalcin S. Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience // J. Oncol. 2019. Vol. 2019. Art. № 5483791. DOI: 10.1155/2019/5483791
Chang A.E., Wu Q.V., Jenkins I.C., Specht J.M., Gadi V.K., Gralow J.R., Salazar L.G., Kurland B.F., Linden H.M. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer // Clin. Breast Cancer. 2018. Vol. 18, № 1. P. e143–e149. DOI: 10.1016/j.clbc.2017.10.005
Zhong H., Lai Y., Zhang R., Daoud A., Feng Q., Zhou J., Shang J. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway // Int. J. Mol. Sci. 2020. Vol. 21, № 3. Art. № 957. DOI: 10.3390/ijms21030957
Ledzewicz U., Schättler H. Application of Mathematical Models to Metronomic Chemotherapy: What Can Be Inferred from Minimal Parameterized Models? // Cancer Lett. 2017. Vol. 401. P. 74–80. DOI: 10.1016/j.canlet.2017.03.021
References
Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. (eds.). Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2021 godu [The State of Cancer Care for the Population of Russia in 2021]. Moscow, 2022. 239 p.
Chubenko V.A., Zagorskaya L.A., Chubenko V.S., Moiseenko F.V., Abduioeva N.H., Zhabina A.S., Kramchaninov M.M., Shelekhova K.V., Meldo A.A., Zykov E.M., Kudryavtsev A.A., Napol’skaya E.V., Moiseenko V.M. Metronomnaya terapiya: mesto v lechenii zlokachestvennykh opukholey [ Metronomic Chemotherapy: Efficacy in Real Clinical Practice]. Prakticheskaya onkologiya, 2019, vol. 20, no. 4, pp. 289–298. DOI: 10.31917/2004289
Fedyanin M.Yu., Pokataev I.A., Tyulyandin S.A. Metronomnye rezhimy khimioterapii v onkologii [Metronomic Chemotherapy Regimens in Oncology]. Onkologicheskaya koloproktologiya, 2016, vol. 6, no. 1, pp. 27–35. DOI: 10.17650/2220-3478-2016-6-1-27-35
Dodokhova M.A., Alkhuseyn-Kulyaginova M.S., Safronenko A.V., Kotieva I.M., Shpakovskiy D.B., Milaeva E.R. Vliyanie tsisplatina i gibridnogo olovoorganicheskogo soedineniya v malykh dozakh na rost i metastazirovanie epidermoidnoy kartsinomy Lewis v eksperimente [Effect of Cisplatin and Hybrid Organotin Compound in Low Doses on the Growth and Metastasis of Lewis Epidermoid Carcinoma in Experiment]. Eksperimental’naya i klinicheskaya farmakologiya, 2021, vol. 84, no. 8, pp. 32–35. DOI: 10.30906/0869-2092-2021-84-8-32-35
Wysocki P.J., Lubas M.T., Wysocka M.L. Metronomic Chemotherapy in Prostate Cancer. J. Clin. Med., 2022, vol. 11, no. 10. Art. no. 2853. DOI: 10.3390/jcm11102853
Maiti R. Metronomic Chemotherapy. J. Pharmacol. Pharmacother., 2014, vol. 5, no. 3, pp. 186–192. DOI: 10.4103/0976-500X.136098
Kerbel R.S. Inhibition of Tumor Angiogenesis as a Strategy to Circumvent Acquired Resistance to Anti-Cancer Therapeutic Agents. Bioessays, 1991, vol. 13, no. 1, pp. 31–36. DOI: 10.1002/bies.950130106
Hanahan D., Bergers G., Bergsland E. Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice. J. Clin. Invest., 2000, vol. 105, no. 8, pp. 1045–1047. DOI: 10.1172/JCI9872
Qiu H., Wang G.-M. A New Treatment Protocol Targeting Tumor Vasculature – Metronomic Chemotherapy Combined Radiotherapy. Ai Zheng, 2007, vol. 26, no. 12, pp. 1392–1396.
Khachatryan L.A., Shcherbakov А.P., Chikvina I.I., Nikolaeva D.M. New Approaches for Solving the Old Problem. Pediatr. Hematol. Oncol. Immunopathol., 2022, vol. 21, no. 1, pp. 122–135 (in Russ.). DOI: 10.24287/1726-1708-2022-21-1-122-135
Norrby K. Metronomic Chemotherapy and Anti-Angiogenesis: Can Upgraded Pre-Clinical Assays Improve Clinical Trials Aimed at Controlling Tumor Growth? APMIS, 2014, vol. 122, no. 7, pp. 565–579. DOI: 10.1111/apm.12201
Kim J.Y., Kim Y.-M. Tumor Endothelial Cells as a Potential Target of Metronomic Chemotherapy. Arch. Pharmacal Res., 2019, vol. 42, no. 1, pp. 1–13. DOI: 10.1007/s12272-018-01102-z
Allegrini G., Falcone A., Fioravanti A., Barletta M.T., Orlandi P., Loupakis F., Cerri E., Masi G., Di Paolo A., Kerbel R.S., Danesi R., Del Tacca M., Bocci G. A Pharmacokinetic and Pharmacodynamic Study on Metronomic Irinotecan in Metastatic Colorectal Cancer Patients. Br. J. Cancer, 2008, vol. 98, no. 8, pp. 1312–1319. DOI: 10.1038/sаj.bjc.6604311
Cazzaniga M.E., Cordani N., Capici S., Cogliati V., Riva F., Cerrito M.G. Metronomic Chemotherapy. Cancers (Basel), 2021, vol. 13, no. 9. Art. no. 2236. DOI: 10.3390/cancers13092236
Krajnak S., Battista M.J., Hasenburg A., Schmidt M. Metronomic Chemotherapy for Metastatic Breast Cancer. Oncol. Res. Treat., 2022, vol. 45, no. 1-2, pp. 12–17. DOI: 10.1159/000520236
Chen Y.-P., Liu X., Zhou Q., Yang K.-Y., Jin F., Zhu X.-D., Shi M., Hu G.-Q., Hu W.-H., Sun Y., et al. Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Multicentre, OpenLabel, Parallel-Group, Randomised, Controlled, Phase 3 Trial. Lancet, 2021, vol. 398, no. 10297, pp. 303–313. DOI: 10.1016/S0140-6736(21)01123-5
Cazzaniga M.E., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., et al. Metronomic Chemotherapy (mCHT) in Metastatic Triple-Negative Breast Cancer (TNBC) Patients: Results of the VICTOR-6 Study. Breast Cancer Res. Treat., 2021, vol. 190, no. 3, pp. 415–424. DOI: 10.1007/s10549021-06375-5
Banys-Paluchowski M., Ruckhäberle E., Schütz F., Krawczyk N., Fehm T. Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer – a Systematic Review of the Literature. Geburtshilfe Frauenheilkd., 2017, vol. 77, no. 2, pp. 142–148. DOI: 10.1055/s-0043-100388
Orlandi P., Di Desidero T., Salvia G., Muscatello B., Francia G., Bocci G. Metronomic Vinorelbine Is Directly Active on Non Small Cell Lung Cancer Cells and Sensitizes the EGFRL858R/T790M Cells to Reversible EGFR Tyrosine Kinase Inhibitors. Biochem. Pharmacol., 2018, vol. 152, pp. 327–337. DOI: 10.1016/j.bcp.2018.04.011
El Darsa H., El Sayed R., Abdel-Rahman O. What Is the Real Value of Metronomic Chemotherapy in the Treatment of Gastrointestinal Cancer? Expert Opin. Pharmacother., 2021, vol. 22, no. 17, pp. 2297–2302. DOI: 10.1080/14656566.2021.1940953
Zsiros E., Lynam S., Attwood K.M., Wang C., Chilakapati S., Gomez E.C., Liu S., Akers S., Lele S., Frederick P.J., Odunsi K. Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol., 2021, vol. 7, no. 1, pp. 78–85. DOI: 10.1001/jamaoncol.2020.5945
Bondarenko M., Le Grand M., Shaked Y., Raviv Z., Chapuisat G., Carrère C., Montero M.-P., Rossi M., Pasquier E., Carré M., André N. Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer. Cancers (Basel), 2021, vol. 13, no. 9. Art. no. 2239. DOI: 10.3390/cancers13092239
Peristeri D.V., Tepelenis K., Karampa A., Kapodistrias N., Goussia A.C., Pappas-Gogos G., Glantzounis G.K. Metronomic Chemotherapy with Cyclophosphamide for the Treatment of Advanced Hepatocellular Cancer: A Case Report. Ann. Med. Surg. (Lond.), 2021, vol. 72. Art. no. 103043. DOI: 10.1016/j.amsu.2021.103043
Su N.-W., Chen Y.-J. Metronomic Therapy in Oral Squamous Cell Carcinoma. J. Clin. Med., 2021, vol. 10, no. 13. Art. no. 2818. DOI: 10.3390/jcm10132818
Isono-Taniguchi R., Goto M., Takimoto Y., Ueda T., Wakimoto Y., Inoue K., Hori K., Ito K., Tsubamoto H. Metronomic Chemotherapy Using Oral Cyclophosphamide and Bevacizumab for Recurrent Cervical Cancer: A MultiInstitutional Retrospective Study. Gynecol. Oncol. Rep., 2022, vol. 42. Art. no. 101013. DOI: 10.1016/j.gore.2022.101013
Sharma A., Kataria B., Biswas B., Bakhshi S., Pushpam D. Oral Metronomic Chemotherapy Is a Cost Effective Alternative to Pazopanib in Advanced Soft Tissue Sarcoma. J. Oncol. Pharm. Pract., 2022, vol. 28, no. 3, pp. 560–568. DOI: 10.1177/10781552211000113
Noronha V., Patil V.M., Menon N.S., Joshi A., Goud S., More S., Kannan S., Pawar A., Nakti D., Yadav A., Shah S., Mahajan A., Janu A., Kumar R., Tibdewal A., Mummudi N., Agarwal J.P., Banavali S.D., Prabhash K. Oral Metronomic Chemotherapy After Definitive Chemoradiation in Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. Esophagus, 2022, vol. 19, no. 4, pp. 670–682. DOI: 10.1007/s10388-022-00923-8
Arrivi G., Spada F., Frassoni S., Bagnardi V., Laffi A., Rubino M., Gervaso L., Fazio N. Metronomic Chemotherapy in Patients with Advanced Neuroendocrine Tumors: A Single-Center Retrospective Analysis. J. Neuroendocrinol., 2022, vol. 34, no. 10. Art. no. e13189. DOI: 10.1111/jne.13189
Isacoff W.H., Cooper B., Bartlett A., McCarthy B., Yu K.H. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer. Cancers (Basel), 2022, vol. 14. Art. no. 2906. DOI: 10.3390/cancers14122906
Patil V., Noronha V., Dhumal S.B., Joshi A., Menon N., Bhattacharjee A., Kulkarni S., Ankathi S.K., Mahajan A., Sable N., Nawale K., Bhelekar A., Mukadam S., Chandrasekharan A., Das S., Vallathol D., D’Souza H., Kumar A., Agrawal A., Khaddar S., Rathnasamy N., Shenoy R., Kashyap L., Rai R.K., Abraham G., Saha S., Majumdar S., Karuvandan N., Simha V., Babu V., Elamarthi P., Rajpurohit A., Kumar K.A.P., Srikanth A., Ravind R., Banavali S., Prabhash K. Low-Cost Oral Metronomic Chemotherapy versus Intravenous Cisplatin in Patients with Recurrent, Metastatic, Inoperable Head and Neck Carcinoma: An Open-Label, Parallel-Group, Non-Inferiority, Randomised, Phase 3 Trial. Lancet Glob. Health, 2020, vol. 8, no. 9, pp. e1213–e1222. DOI: 10.1016/S2214-109X(20)30275-8
Simsek C., Esin E., Yalcin S. Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience. J. Oncol., 2019, vol. 2019. Art. no. 5483791. DOI: 10.1155/2019/5483791
Chang A.E., Wu Q.V., Jenkins I.C., Specht J.M., Gadi V.K., Gralow J.R., Salazar L.G., Kurland B.F., Linden H.M. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clin. Breast Cancer, 2018, vol. 18, no. 1, pp. e143–e149. DOI: 10.1016/j.clbc.2017.10.005
Zhong H., Lai Y., Zhang R., Daoud A., Feng Q., Zhou J., Shang J. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway. Int. J. Mol. Sci., 2020, vol. 21, no. 3. Art. no. 957. DOI: 10.3390/ijms21030957
Ledzewicz U., Schättler H. Application of Mathematical Models to Metronomic Chemotherapy: What Can Be Inferred from Minimal Parameterized Models? Cancer Lett., 2017, vol. 401, pp. 74–80. DOI: 10.1016/j.canlet.2017.03.021
